PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 131 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $100,000 | -24.8% | 26,200 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $133,000 | +3.9% | 26,200 | +3.6% | 0.00% | -20.0% |
| Q3 2019 | $128,000 | -17.9% | 25,290 | 0.0% | 0.01% | -54.5% |
| Q2 2019 | $156,000 | +35.7% | 25,290 | +2.1% | 0.01% | +37.5% |
| Q1 2019 | $115,000 | +12.7% | 24,780 | +2.2% | 0.01% | +33.3% |
| Q4 2018 | $102,000 | -38.9% | 24,250 | +16.7% | 0.01% | -33.3% |
| Q2 2018 | $167,000 | -20.1% | 20,780 | -26.0% | 0.01% | -10.0% |
| Q1 2018 | $209,000 | +33.1% | 28,070 | +6.5% | 0.01% | +25.0% |
| Q4 2017 | $157,000 | -19.1% | 26,350 | 0.0% | 0.01% | -20.0% |
| Q3 2017 | $194,000 | +71.7% | 26,350 | +58.7% | 0.01% | +66.7% |
| Q2 2017 | $113,000 | -25.2% | 16,600 | +4.0% | 0.01% | -14.3% |
| Q1 2017 | $151,000 | – | 15,960 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |